Off-label uses of sorafenib and sunitinib.
D000230:Adenocarcinoma / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D017326:Clinical Trials, Phase III as Topic; D004067:Digestive System Neoplasms / Q000188:drug therapy; D017277:Drug Approval; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy; D011356:Product Labeling; D011725:Pyridines / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011725:Pyridines; D011758:Pyrroles